Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.82 USD
Change Today +0.26 / 1.57%
Volume 333.5K
RGLS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Snapshot

Open
$16.58
Previous Close
$16.56
Day High
$17.15
Day Low
$16.29
52 Week High
11/10/14 - $25.60
52 Week Low
05/9/14 - $5.40
Market Cap
849.7M
Average Volume 10 Days
532.9K
EPS TTM
$-1.12
Shares Outstanding
50.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGULUS THERAPEUTICS INC (RGLS)

regulus therapeutics inc (RGLS) Related Businessweek News

View More BusinessWeek News

regulus therapeutics inc (RGLS) Details

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. It uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. The company’s clinical stage products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection; and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease. It has strategic collaborations with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases. The company also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 preclinical fibrosis program for the treatment of Alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

81 Employees
Last Reported Date: 02/19/15
Founded in 2007

regulus therapeutics inc (RGLS) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $600.0K
Chief Scientific Officer
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

regulus therapeutics inc (RGLS) Key Developments

Regulus Therapeutics Inc. Receives Orphan Medicinal Product Designation from European Commission for RG-012

Regulus Therapeutics Inc. announced that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 (miR-21) for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. In July 2014, the U.S. Food & Drug Administration granted orphan drug designation to RG-012 for the treatment of Alport syndrome.

Regulus Therapeutics Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 03:05 PM

Regulus Therapeutics Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 03:05 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Paul C. Grint, Chief Medical Officer.

Regulus Therapeutics Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Regulus Therapeutics Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of $12,635,000 against profit from operations of $2,716,000 for the same period a year ago. Loss before income taxes was $22,168,000 against $1,946,000 for the same period a year ago. Net loss of $22,168,000 or $0.47 diluted loss per share against $1,927,000 or $0.11 diluted per share for the same period a year ago. Total Revenue was $4,219,000 against $5,454,000 for the same period a year ago. For the year, the company reported loss from operations of $44,910,000 against profit from operations of $17,802,000 for the same period a year ago. Loss before income taxes was $56,679,000 against $18,691,000 for the same period a year ago. Net loss of $56,680,000 or $1.29 diluted loss per share against $18,668,000 or $0.49 diluted per share for the same period a year ago. Total Revenue was $7,669,000 against $19,569,000 for the same period a year ago. The increase in net loss was primarily attributable to increases in the value of common stock in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $16.82 USD +0.26

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGLS.
View Industry Companies
 

Industry Analysis

RGLS

Industry Average

Valuation RGLS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit www.regulusrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.